The Latest Malaria News, in 60 Seconds.

Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.

Malaria Minute on iTunes and Spotify


Transcript:

Whilst many of the vaccine candidates against malaria aim to provide protection against Plasmodium parasites, to date there has not been a vaccine evaluated in humans targeted towards the mosquito itself. Preclinical studies have suggested that antibodies to mosquito saliva may provide some protection against mosquito-borne diseases, and this could also apply to malaria. In a new clinical trial, researchers assessed the immunogenicity of the AGS-v vaccine, which aims to induce antibodies against saliva produced by Anopheles gambiae, the main malaria vector in Africa. 49 participants were assigned to either a vaccine-only group, an adjuvanted vaccine group or a placebo group. The vaccine was well-tolerated in all cases and most immunogenic when given with adjuvant, resulting in a significant increase in vaccine-specific IgG antibodies and also the cytokines interferon-gamma. If the vaccine provides protection, it could help to control malaria.

Sources:

Safety and Immunogenicity of a Mosquito Saliva Peptide-Based Vaccine: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Trial


Image Credits: CDC/ James Gathany [18754]

Scientific Advisor: Katharine Collins, Radboud University Medical Centre

Print Friendly, PDF & Email
Categories: Malaria Minute

Stay Informed

Keep up to date with the latest malaria news.